ReviewBest practice & research. Clinical gastroenterology2010
The integrity of the esophageal mucosa. Balance between offensive and defensive mechanisms.
Review in Best practice & research. Clinical gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Gastrointestinal microbiota alterations associated with pediatric gastroesophageal reflux disease and proton pump inhibitor exposure: a systematic review of microbiome changes, dysbiosis markers, and associated clinical outcomes.Frontiers in nutrition · 2026Pooled it
- A gene therapy approach to prevent dilated intercellular space, a hallmark of gastroesophageal reflux disease.Gene therapy · 2026Article
- Systemic inflammatory biomarkers in gastroesophageal reflux disease: current evidence and future perspectives.Frontiers in medicine · 2026Review
- Cross-tissue enrichment patterns reveal functional clustering in normal human tissues from GTEx.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Impairment of Esophageal Barrier Integrity: New Insights into Esophageal Symptoms in Post-COVID-19.Digestive diseases and sciences · 2025Article
- Effective Restoration of Gastric and Esophageal Tissues in an In Vitro Model of GERD: Mucoadhesive and Protective Properties of Xyloglucan, Pea Proteins, and Polyacrylic Acid.International journal of molecular sciences · 2025Article
- A Non-Pharmacological Paradigm Captures the Complexity in the Mechanism of Action of Poliprotect Against Gastroesophageal Reflux Disease and Dyspepsia.International journal of molecular sciences · 2025Article
- Global Transcriptomic Analysis of Topical Sodium Alginate Protection against Peptic Damage in an In Vitro Model of Treatment-Resistant Gastroesophageal Reflux Disease.International journal of molecular sciences · 2024Article
- Jag1/2 maintain esophageal homeostasis and suppress foregut tumorigenesis by restricting the basal progenitor cell pool.Nature communications · 2024Article
- Alterations in gene expression and microbiome composition upon calcium-sensing receptor deletion in the mouse esophagus.American journal of physiology. Gastrointestinal and liver physiology · 2024Article
- The last step to achieve barrier damage control.Frontiers in immunology · 2024Article
- Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors.Drug delivery · 2023Review
- Revisiting the Role of Esophageal Mucosal Dilated Intercellular Spaces in the Diagnosis and Pathophysiology of Heartburn.Journal of neurogastroenterology and motility · 2023Article
- Esophageal Mucosal Resistance in Reflux Esophagitis: What We Have Learned So Far and What Remains to Be Learned.Diagnostics (Basel, Switzerland) · 2023Review
- Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction.International journal of molecular sciences · 2023Article
- NF-κB: A novel therapeutic pathway for gastroesophageal reflux disease?World journal of clinical cases · 2022Review
- Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases.The FEBS journal · 2022Review
- Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis.Digestive diseases and sciences · 2022Article
- Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid-induced DNA damage.Clinical and translational medicine · 2022Article
- Lycopodium Mitigates Oxidative Stress and Inflammation in the Colonic Mucosa of Acetic Acid-Induced Colitis in Rats.Molecules (Basel, Switzerland) · 2022Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Heartburn is the most common and characteristic symptom of gastroesophageal reflux disease. It ultimately results from contact of refluxed gastric acid with nociceptors within the esophageal mucosa and transmission of this peripheral signal to the central nervous system for cognition. Healthy esophageal epithelium provides an effective barrier between refluxed gastric acid and esophageal nociceptors; but this barrier is vulnerable to attack and damage, particularly by acidic gastric contents. How gastric acid is countered by defensive elements within the esophageal mucosa is a major focus of this discussion. When the defense is successful, the subject is asymptomatic and when unsuccessful, the subject experiences heartburn. Those with heartburn commonly fall into one of three endoscopic types: nonerosive reflux disease, erosive esophagitis and Barrett's esophagus. Although what determines endoscopic type remains unknown; it is proposed herein that inflammation plays a key, modulating role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.